Quick answer
Preserve the source medication meaning before mapping it to a target concept. Compare ingredient, strength, dose form and other required attributes; retain source codes and versions; and route ambiguous or unsupported mappings for qualified review. A high mapping percentage does not prove clinically appropriate equivalence.
Define what the target concept must mean
A SNF receives medication data from several sources. One sends a branded product, another sends an ingredient and strength, and an older record contains only free text. Mapping all three to a convenient local label can conceal differences that matter downstream.
The National Library of Medicine's RxNorm overview explains normalized drug names and relationships among ingredient, strength, dose form and branded concepts. It also describes source vocabularies, releases and scope limits. Use that model to ask precise mapping questions; RxNorm is not a substitute for prescribing judgment or proof of therapeutic equivalence.
Specify the purpose first. Displaying a historical medication, reconciling an active list, transmitting an order and grouping data for analysis may require different levels of detail. A mapping acceptable for one purpose should not silently authorize another.
Preserve both source and target
For each mapping, retain the original code system, code, display, source version where available, received text, target system/code/version, mapping method, reviewer and effective date. Keep unmapped values visible. Replacing the source with only the target label makes later investigation harder.
This original test pack uses abstract medication descriptions rather than prescribing examples:
| Source case | Mapping question | Expected handling |
|---|---|---|
| Ingredient, strength and tablet form present | Does the target preserve every required attribute? | Qualified verification of the exact concept |
| Same ingredient and strength, different release form | Is a clinically meaningful distinction being lost? | Do not merge solely on ingredient/strength |
| Brand and generic concepts | What relationship is intended for this use? | Preserve original identity and reviewed relationship |
| Concentration expressed in different units | Are units and basis equivalent? | Validate conversion and meaning before use |
| Free text with missing strength | Is a sufficiently specific target justified? | Hold or use explicitly limited representation |
| Retired source code | What historical meaning and replacement guidance exist? | Version-aware review rather than blind reassignment |
Measure unresolved meaning, not just coverage
A fictional feed contains 1,000 medication records. An automated service maps 950, but review finds 30 mapped only at ingredient level where the intended workflow needs product-level detail. The useful result is not simply “95% mapped.” Report exact approved mappings, intentionally broader mappings for a limited purpose, unresolved cases and rejected mappings separately.
Sample high-consequence and uncommon cases deliberately. A random sample dominated by common products can miss dosage-form and unit failures. Clinical or pharmacy reviewers should select representative edge cases and define which transformations require human review.
Test downstream behavior
After mapping, inspect the medication display, source provenance, reconciliation workflow and receiving-system output. Confirm that a broad historical representation does not become a fully specified active order. An interface may preserve the code but truncate the display or drop the unit; end-to-end observation matters.
Test missing codes, conflicting code/display pairs and multiple candidate matches. The system should expose uncertainty rather than select the first search result. A human-readable source value can be useful while a mapping is unresolved, provided the workflow clearly communicates its status and limits.
Manage terminology releases as changes
Record the terminology release and mapping-table version used for each processing period. Evaluate newly introduced, changed and retired concepts before deployment. Re-run the selected edge cases and inspect changes in unresolved rates. A mapping update that improves coverage can still alter previously accepted meaning.
Decide whether historical records retain the mapping used at the time or receive a reviewed reinterpretation for a specific purpose. Preserve the distinction so a later analyst can reproduce earlier results. Do not rewrite clinical history without an appropriate process.
Buy maintainable semantic support
Ask who maintains mappings, which terminologies and versions are supported, how unresolved values reach qualified reviewers and what evidence accompanies updates. Include local dictionary work and ongoing clinical review in the implementation effort.
The acceptance output is a traceable mapping register and demonstrated downstream meaning for the selected use cases. It allows a SNF buyer to assess interoperability beyond the fact that messages arrived and codes were populated.
Questions & answers
Is matching an ingredient enough to map a medication?
Not when the intended target requires strength, dose form or other distinctions. The necessary granularity depends on the use and must be reviewed.
Does RxNorm mapping establish therapeutic interchangeability?
No. Terminology alignment is not a prescribing or substitution decision. Qualified clinical and pharmacy review remains necessary.
Primary sources
Use the cited source and its applicable version when making a facility-specific decision. These guides explain operational evaluation methods; they are not individualized clinical, coding, or legal advice.